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ABSTRACT

Recently, human maternal placenta ingestion, known as placentophagy, has emerged
as a rare but growing practice among postpartum mothers in industrialized societies, and
is currently found in both home birth and hospital birth settings. The practice is purported
to result in certain health benefits for postpartum mothers, some of which could be
related to the iron content in full-term placenta (e.g., increased energy and an improved
and more rapid postpartum recovery, among others). The aim of this research project was
to investigate the effect of encapsulated placentophagy on maternal postpartum iron
status via a randomized, double-blind, placebo-controlled pilot study (n=28). The
majority of participants were Caucasian (79%), with at least some college education
(88.7%), and married or in a domestic partnership (87%). Maternal iron status of women
in the placenta supplement group (n=12), the placebo group (n=16), and an additional
iron-supplement comparison group (n=3) was measured via hemoglobin, transferrin, and
ferritin taken from blood samples at four time points; the 36th week of pregnancy, within
72 hours of parturition, between days five and seven postpartum, and during week three
postpartum. All participants also completed a Willet Food Frequency Questionnaire in
order to assess dietary iron intake during the study period. Results reveal no statistically
significant differences in the maternal iron status of women in the placenta supplement
and placebo (beef or vegetarian supplements) groups. While the small sample size of the
additional (over-the-counter) oral iron supplement group did not allow for statistical
comparison with the placenta supplement and placebo groups, maternal iron status of
these participants varied only slightly from those of placenta supplement and placebo
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group participants. The current study suggests that encapsulated placenta
supplementation neither significantly improves, nor impairs postpartum maternal iron
status for women consuming at least adequate amounts of dietary iron.
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CHAPTER 1

INTRODUCTION AND STUDY AIMS
Introduction
Recently, the practice of human maternal placenta ingestion, known as placentophagy,
has gained popularity among mothers in industrialized societies, who cite its many
purported health benefits. As the practice has become more common, increasingly
human placentophagy is spreading from natural home birth settings to hospital births.
Advocates of this practice cite the ubiquity of placentophagy among mammals generally
and note the hypothesized adaptive value of the behavior for mammalian mothers put
forward by scientists (e.g., maternal pain reduction, increased milk production, and
postpartum nutrition). Among human mothers, this practice is purported to result in
many benefits including increased energy, and improved and more rapid postpartum
recovery, among others. Such benefits may be related to the iron content in full-term
placenta (Bradley, et al., 2004). Many pregnant and postpartum women are advised by
medical professionals to take iron supplements in order to prevent or reverse irondeficiency and iron-deficiency anemia (IDA) (Bodnar, Cogswell, & McDonald, 2005).
Iron-deficiency and IDA are characterized mainly by fatigue, followed by additional
symptoms of pallor, weakness, labored breathing, headache, palpitations, and dizziness
(Pavord, Myers, Robinson, Allard, Strong, & Oppenheimer, 2012). Many new mothers
choose to ingest their placenta as a “natural” alternative to hormone and nutrient
supplements (PlacentaBenefits.info, 2015). Heme (i.e., animal sources) iron, in particular,
may be an important component of these placenta supplements, potentially allowing
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women an especially rapid recovery from deficiency, something currently unavailable to
them with standard plant-based iron supplements or perhaps other forms of dietary iron
(Pavord et al., 2012). Some placentophagic mothers have claimed their physicians noted
an especially rapid postpartum iron rebound, and have attributed this recovery to placenta
capsule ingestion (Young S.M., 2012).
The placenta is a highly vascularized, iron-rich organ (Bradley, et al., 2004).
Placentophagy advocates propose that ingesting the organ in any form (e.g. raw, cooked,
or dried and encapsulated) will provide all of the necessary iron required for postpartum
mothers. This research project evaluates the efficacy of such claims by means of a
clinically controlled comparison of postpartum maternal iron status. The project was
conducted among 3 groups: women ingesting placenta supplements, women ingesting a
vegetable or beef-based placebo, and women ingesting traditional ferrous sulfate iron
supplements. The results of this study provide an objective evaluation of placentophagy
advocates’ claims of a more rapid iron rebound for postpartum women, as these claims
have never been evaluated through rigorous scientific testing.

General Aims of the Study
Research on the emerging practice of human placentophagy can help inform pregnant
and postpartum women about the potential benefits and risks of ingesting their placenta.
The results of the current study may aide women in making more informed decisions
about their own health and that of their offspring. The dominant narrative among
placentophagy advocates revolves around the “natural” aspects and benefits of the
practice (PlacentaBenefits.info, 2015), despite its conspicuous absence as a traditional
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practice in contemporary human societies. Recent cross-cultural research reveals that
while the ritual treatment/disposal of the placenta is central to many cultural beliefs and
customs, consumption of the placenta is all but unknown. The single ethnographic case
of placentophagy comes from Chicano culture, likely part of the recently emerging
practice and not evidence of traditional consumption (Young & Benyshek, 2010).
It is important that women engaging in placentophagy know precisely what they are
consuming. While women understand that they are ingesting placenta, there is only a
vague idea of human placental composition. Most information women receive about this
practice is anecdotal and provided by maternal human placentophagy proponents.
Rigorous scientific studies can be used help to gain a clearer picture of precisely what,
and how much they are ingesting. To date, the potential health benefits or risks of
maternal placentophagy have not been scientifically assessed in humans. The public
health implications may be significant. Discerning how placentophagy may effect
maternal iron status immediately postpartum, and compared to standard over-the-counter
oral iron supplements is especially important information for new mothers, and may be
especially important for iron deficient or IDA women that choose to forego traditional
over the counter (OTC) iron supplements in favor of placentophagy. For these women,
iron uptake via placenta capsules (over the course of several weeks) must be sufficient to
amend iron deficits. Because iron deficiency and IDA are associated with negative health
outcomes for mother and child, this issue is particularly important and relevant.
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CHAPTER 2

LITERATURE REVIEW
Mammalian Placentophagy
Maternal placentophagy, or the consumption of the placenta or afterbirth postpartum
is a ubiquitous behavior among terrestrial mammal mothers. Nearly all of the more than
4,000 terrestrial mammalian species consume the placenta after birth: carnivore,
herbivore, and omnivore alike. The only exceptions are camelids, and possibly, humans.
Recently, a very small but growing number of women in industrialized countries are
ingesting their placentas postpartum in the belief that it will improve recovery after
delivery, increase lactation, and protect against postpartum mood disorders, amongst
other purported benefits (Selander, Cantor, Young, & Benyshek, 2013). Many
placentophagy advocates have cited non-human mammalian placentophagy to justify the
practice among human mothers (PlacentaBenefits.info, 2015). Cross-cultural instances of
this practice in human populations, however, are exceedingly rare to non-existent; a 2010
review of the cross-cultural literature regarding placenta treatment and disposal practices
found no evidence of placentophagy as a longstanding traditional practice in any culture
(Young & Benyshek, 2010).
Kristal and colleagues have described the most prevalent speculative explanations for
placentophagy among mammals generally (Kristal, DiPirro, & Thompson, 2012). The
first of these hypotheses states that, “the mother undergoes a shift in food preference
toward carnivorousness at the time of parturition” (Kristal, 1980). A second proposes that,
“mothers eat the afterbirth to maintain the cleanliness of the nest site and to avoid
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attracting predators” (Kristal, 1980). While compelling, these hypotheses alone do not
provide sufficient explanations for the practice across taxa.
Hypothesis 3 states “that mothers consume the afterbirth because of general hunger,
i.e., that anorexia prior to parturition leads to placentophagy as a means of maintaining
homeostatic food intake requirements” (Kristal, 1980); and a fourth hypothesis “that
placentophagy is a response to specific hunger, i.e., a response to specific nutritional or
hormonal needs which can be satisfied by consuming the afterbirth” (Kristal, 1980).
The hypothesis of general hunger applies to animals that fast prior to parturition,
which may include humans, depending upon the culture studied. Maternal “anorexia prior
to parturition leads to placentophagy as a means of maintaining homeostatic food intake
requirements” (Kristal, 1980). There is also evidence of fasting among non-human
animals (e.g. dogs, horses) prior to parturition (Kristal, 1980).
Finally, specific hunger occurs when nutritional deficiencies result in cravings for
substances rich in those nutrients (e.g. iron, zinc, or calcium), hormones (e.g., oxytocin or
progesterone) or endogenous opioid or opioid factors (e.g., placental opioid enhancing
factor). It should be noted, however, that placentophagy among mammals is not strictly a
maternal behavior, as the general and specific hunger hypotheses might imply. Some
mammals, such as hamsters, consume the placenta crossing age, sex, and reproductive
history lines (Gregg & Wynne-Edwards, 2005; Gregg & Wynne-Edwards, 2006).
Because of the demands of pregnancy, however, postpartum mothers are more likely to
suffer from nutritional deficiencies, and those found in the placenta may reestablish
maternal nutritional sufficiency. Of specific interest to this study is the micronutrient
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iron, which is depleted through pregnancy, blood loss during the birthing process, and
demands on the postpartum mother through lactation.
Some women with iron deficiency or IDA experience pica, a craving for nonnutritive substances rich in certain micronutrients. In one study conducted in South
Africa, 10 iron deficient women were engaging in pica by ingesting dry soil and paper,
two of whom were pregnant (Walker, Walker, Sookaria, & Cannan, 1997). Another form
of pica known as pagophagy (ice consumption) has been correlated with iron deficiencies
in some women, wherein pagophagy either diminishes or disappears after iron treatment
(Young S. L., 2010). In another analysis, Young and colleagues assessed over 482
cultural-level accounts for reports of human geophagy while additionally assessing
accounts of 297 species that have engaged in geophagy across taxa. Ultimately they
found that geophagy among humans is more closely associated with curbing illness from
parasites or toxic substances, as opposed to compensating for any nutritional deficiencies
(Young, Sherman, Lucks, & Pelto, 2011). Evidence supporting iron-related geophagy is
controversial, as not all women engaging in the practice are iron deficient, and the
practice among humans in general may have little to do with nutrition. Today most
mothers in industrialized countries have easy access to iron supplements to prevent or
treat iron deficiency during or immediately after parturition.

Iron
The placenta is a vascularized, iron-rich organ. Additionally, iron is a highly heatstable nutrient. Combined, these two aspects may place the modern practice of human
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placentophagy in the unique position of providing adequate iron supplies necessary for
postpartum women.
Iron is also an essential nutrient. It is required for the formation of red blood cells
(RBCs). The majority (~70%) of iron is found in hemoglobin bound to RBCs, while the
remainder is found as transferrin produced by the liver and present in blood, or as ferritin
stored in the liver, spleen, skeletal muscles, and bone marrow (Thompson & O'Donnell,
2010). Iron is essential to RBCs in: a) transporting oxygen from the lungs to tissues in the
body, and b) transferring carbon dioxide waste back to the lungs for expulsion (Erickson,
1996). When sufficient amounts of iron stores have been depleted, iron deficiency and,
eventually, the more severe, anemic form of iron deficiency, IDA, will result.
There are different causes of anemia, a condition characterized by a lack of healthy
RBCs or hemoglobin in the blood. Iron deficiency is the most prevalent cause of anemia
and is initiated through different mechanisms (e.g. chronic or rapid bleeding, insufficient
dietary iron intake). Sickle cell trait, malaria, HIV, certain infectious diseases, and other
nutritional deficiencies (e.g. folate, vitamin A) may also cause anemia (Stoltzfus, 2001).
Regardless of its etiology, the result of anemia is the same: insufficient transport of
oxygen to tissues.
The simplest, most accessible method for testing iron deficiency is that of
hemoglobin concentration (for RBCs). The standard clinical cutoff value for hemoglobin
for pregnant women is 11 g/dL, and 12 g/dL for non-pregnant women 15 years of age or
older (World Health Organization, 2011). Blood donators are screened via this method
for that reason; however, it has been shown that approximately 20% of donors with
normal hemoglobin concentrations are nevertheless iron deficient (Ghosh, 2012). This is
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known as ‘subclinical iron deficiency’. If multiple methods of measurement are not
administered, an accurate view of iron status will not be obtained. For diagnostic and
research purposes, medical practitioners and scientists may choose to test hemoglobin,
serum iron, transferrin, transferrin saturation, ferritin, and total iron-binding capacity
(TIBC), or any combination thereof (Khalafallah & Dennis, 2012). Ferritin is the storage
form of iron, and transferrin is the transport form of iron when levels are low. Measuring
hemoglobin, transferrin, and ferritin allows for multiple lines of evidence to determine
iron status, as each analyte is affected by differing confounding factors. Additionally,
hemoglobin, transferrin, and ferritin are commonly tested, due to the comparatively low
cost of analysis and the wide availability and standardization of kits (Khalafallah &
Dennis, 2012). One method used to assess iron deficiency is to measure three iron
markers; if at least two of the three analytes are below expected levels, one can be
classified as iron deficient (Cook, Finch, & Smith, 1976).

Iron and Reproduction
Pregnancy, birth, and the postpartum period are biologically demanding for women
worldwide, across cultural and social categories. While all women are at risk, some are
more likely to experience iron deficiency than others. For example, short inter-birth
intervals (IBIs) and related multiparity lead to increased iron deficiency and IDA
susceptibility. Women need time to replenish iron supplies, but short IBIs do not allow
the time to do so. In such cases women will enter into new pregnancies already depleted,
and by the end of the second pregnancy, iron deficiency is exacerbated (Allen, 2000).
Additionally, obesity and a lack of exclusively breastfeeding infants at postpartum
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checkup (meaning infants are partially or completely bottle fed) have both been identified
as risk factors for postpartum iron deficiency and IDA, particularly among low-income
women (Bodnar et al., 2002). The association between iron deficiency and not
exclusively breastfeeding seems counterintuitive; however, hypotheses have been
proposed to explain this phenomenon. Exclusive breastfeeding may extend lactational
amenorrhea, thus preventing additional iron loss through menstruation, aiding in
maintaining maternal iron supplies. Additionally, breastfeeding may be associated with
women of higher Socio-Economic-Status (SES), engaging in healthier eating practices, or
supplementation compliance (Bodnar et al., 2002).
Research suggests that, in order to meet the demands of pregnancy, women require
300 mg or more in iron stores prior to conception (Viteri & Berger, 2005). Women lose a
total of 1000 mg of iron during pregnancy and lactation, resulting in the need for iron
intake of 27 mg/day during pregnancy (Khalafallah & Dennis, 2012). The Recommended
Dietary Allowance (RDA) for lactating women (age 19-50) is 9 mg/day (Institute of
Medicine. Food and Nutrition Board, 2001). For women with short IBIs and multiple
children, iron supplementation and the consumption of iron-rich and iron-fortified foods
is of utmost importance.
Iron deficiency and IDA can cause problems not only for the mother; there are shortand long-term complications for children of iron deficient mothers. Immediate problems
from maternal anemia occur during birth when hormone function is compromised,
leading to preterm labor and pre-eclampsia which can compromise neonatal outcomes
(Rasmussen, 2001). Rodent studies have shown reductions in offspring birth weight, as
well as high blood pressure at a young age (Lewis, Forhead, Petry, Oxanne, & Hales,
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2002). One study showed that female rhesus monkeys deprived of iron during pregnancy
produced infants with significantly lower hemoglobin, mean corpuscular volume, and
mean corpuscular hemoglobin as compared to controls (Golub, et al., 2006). Results from
the same study showed that prenatally iron-deprived rhesus infants exhibited reduced
activity levels and reduced responses to new environments compared to controls, and
infants deprived of iron postnatally exhibited poor cognitive performance and greater
emotional reactions compared to controls (Golub, Hogrefe, Germann, Capitanio, &
Lozoff, 2006). In humans, infants born to anemic mothers are more likely to become iron
deficient anemic themselves (Colomer, 1990), and IDA is known to negatively affect
mental and motor development (Allen, 2000).
Iron deficiency is a worldwide problem, though the severity varies from country to
country and from one ecological, political, and social context to another. According to
data collected by the World Health Organization from 1993-2005, the global prevalence
of anemia was 24.8% (World Health Organization, 2013). Among women of
reproductive age, this figure increases (41.8% for pregnant women, 30.2% for nonpregnant women) (World Health Organization, 2013). While industrialized nations
display a lower prevalence of iron deficiency, the incidence is nevertheless high and a
major point of concern for health officials. Iron deficiency in Western societies ranges
from 25-40% of pregnant women, that number increasing amongst lower SES
populations (Alwan & Cade, 2011); however, exact figures are difficult to assess due to
the common conflation of anemia and iron deficiency anemia, which has led several
prominent publications to inflate cases of IDA (Stoltzfus, 2001).
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Iron and Mood
A number of studies have linked low levels of iron to mood disorders. It is
hypothesized that anemia, often caused by iron deficiency, increases the risk of
experiencing mood disorders like anxiety and depression (Benton & Donohoe, 1999).
One Australian study found a significant correlation between iron deficient women taking
oral contraceptives and an increased probability of depression (Rangan, Blight, & Binns,
1998). Whether this was due to iron deficiency, oral contraceptives, or a combination of
the two is unknown. A double-blind placebo-controlled study showed a statistically
significant correlation between iron therapy and the improved mood of 16-17 year old
high school females (Ballin, Berar, Rubinstein, Kleter, Hershkovitz, & Meytes, 1992). A
2003 study has linked anemia and postpartum depression: hemoglobin measurements
taken at day seven postpartum identified eight women as anemic; by day 28, seven of
those eight women showed signs of depression (Corwin, Murray-Kolb, & Beard, 2003).

The Evolutionary Theory of IDA
Denic and Argarwal (2007) hypothesize why iron deficiency is so prevalent among
populations, crossing multiple social categories (e.g. countries, SES, sex, age, etc.) and
surviving in the face of public health initiatives to eradicate iron deficiency. They begin
by noting that iron deficiency became common in the Neolithic era with the changes
agriculture and sedentism brought to diet. The authors then go on to propose that diseases
humans had never been exposed to prior to sedentism and its associated crowding, caused
iron deficiency to be favored by natural selection. Multiple lines of evidence have shown
that iron deficiency protects against crowd diseases such as malaria, plague, and
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tuberculosis. Sufficient iron stores are needed to prevent anemia and maintain overall
health, however, iron can also be appropriated to fuel infectious agents. When epidemics
occur, group selection favors those with lower levels of iron because those infectious
agents have less nourishment from which to draw upon. In the face of such harrowing
diseases, the authors argue, iron deficiency is the lesser evil with which the body can
more easily cope. In a sedentary population, those who consumed iron deficient diets
would survive more often than those who received adequate dietary iron. It is believed
that, “multiple evolutionary factors have contributed in making iron deficiency a
successful phenotype” (Denic & Agarwal, 2007, p. 603). Such a selective pressure might
explain why iron deficiency and IDA are common, particularly amongst pregnant and
postpartum women, the focus population of this study.
Where questions of evolutionary adaptation among human populations arise,
anthropologists often look towards modern populations of hunter-gatherers as the closest
analog to the ancestral conditions. If iron deficiency is a byproduct of a shift in food
procurement methods (i.e. agricultural subsistence), then one might imagine that modern
hunter-gatherers would not suffer from iron deficiency to the extent other populations do.
One such study of iron deficiency among the !Kung Bushmen of the Kalahari desert,
conducted in 1971, showed a very low incidence of iron deficiency and anemia, although
these results may have been confounded by the use of cast iron cooking pots – known to
provide nutritional sources of iron (Metz, Hart, & Harpending, 1971). Hunter-Gatherers
are some of the fittest of populations, exercising regularly and with access to a broadspectrum diet. In contrast, sedentary and semi-sedentary communities (e.g.
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horticulturalists, agriculturalists) have far less dietary variety and suffer the most from
nutritional deficiencies.

Iron and Encapsulated Human Placenta
In a study from 2000 conducted in Thailand, researchers analyzed 30 human (15
female, 15 male) heat-dried placentas for hormone and nutrient content. Results show
that heat-treated and granulated placentas contain, on average, 1.01 mg/g of iron
(Phuapradit et al., 2000). According to recommended dosages for the first week
postpartum, women engaging in placentophagy ingest a maximum of 3300 mg/day of
granulated encapsulated placenta (PlacentaBenefits.info, 2015). Recall that the daily
recommended dietary iron intake for lactating females aged 19-50 is 9mg (Institute of
Medicine. Food and Nutrition Board, 2001). Therefore, the amount of iron found in the
placentas in the Phuapradit et al. study represents about 1/3 of the daily recommended
dietary iron intake (3.3 mg of iron per day in placenta supplements).
Based on findings from the study by Phuapradit et al (2000), encapsulated placenta
may provide 33% or more of the recommended dietary iron intake during the first week
postpartum. Iron from meat sources (heme iron) comes in a more bioavailable form than
vegetable sources (nonheme iron), meaning placental iron could have a greater impact
upon dietary needs, compared to a simple nonheme iron supplement of the same dose.
About half of the iron found in meat comes in heme form and has a higher absorption rate
than nonheme iron. Nonheme iron is much more common in food generally, having a
greater overall impact on iron supplies due to its sheer ubiquity. Additionally, nonheme
iron absorption can be inhibited or increased by other dietary factors as well as existing
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iron stores (Monson, 1988). The bioavailability of iron found in placenta may be further
complicated by the hundreds of substances found in human placental tissue, including
many micronutrients, peptide and steroid hormones, and endogenous opioid
neuropeptides, among others. These substances may interact with iron and or otherwise
affect the physiology of postpartum mothers in ways that inhibit or facilitate iron
absorption.
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CHAPTER 3

RESEARCH QUESTIONS AND HYPOTHESES
In order to determine whether the ingestion of placenta capsules affects iron levels of
postpartum women, we compared iron measurements among three groups of women: one
group ingesting typical non-heme iron tablet supplements (Iron Group), a second group
ingesting a placebo made of either beef or vegetarian meat substitute (Placebo Group),
and a third group ingesting their own dehydrated and encapsulated placenta
(Experimental Group).
Null Hypothesis 1: Experimental, Placebo, and Iron Group participants will not show
an increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) measured
during, (a) days five-seven postpartum, and (b) week three postpartum, as compared to
baseline measure taken prior to supplement initiation (within 72 hours postpartum).
Hypothesis 1: Experimental, Placebo, and Iron Group participants will show an
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) measured
during, (a) days five-seven postpartum, and (b) week three postpartum, as compared to
baseline measure taken prior to supplement initiation (within 72 hours postpartum).
Null Hypothesis 1a: Experimental Group participants will not show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared
to Placebo Group and Iron Group participants from baseline (within 72 hours
postpartum) to day five-seven postpartum.
Hypothesis 1a: Experimental Group participants will show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared

!

15

to Placebo Group and Iron Group participants from baseline (within 72 hours
postpartum) to day five-seven postpartum.
Null Hypothesis 1b: Experimental Group participants will not show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared
to Placebo Group and Iron Group participants from baseline to week three postpartum.
Hypothesis 1b: Experimental Group participants will show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared
to Placebo Group and Iron Group participants from baseline to week three postpartum.
Null Hypothesis 1c: Experimental Group participants will not show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared
to Placebo Group and Iron Group participants from days five-seven postpartum to week
three postpartum.
Hypothesis 1c: Experimental Group participants will show a greater interval
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) as compared
to Placebo Group and Iron Group participants from days five-seven postpartum to week
three postpartum.
The timing of each measurement is purposeful. The first measurement, taken during
the 36th week of pregnancy, establishes a pre-supplementation iron baseline. As iron
deficiency during pregnancy increases the likelihood of experiencing postpartum iron
deficiency, this is an important measurement (Allen, 2000). The second measurement,
taken within 72 hours of parturition, establishes the postpartum iron baseline, which can
differ from the pregnancy iron baseline. Assessing iron status between days five-seven
and during week three (days 21-27) respectively, assures that instances of rapid iron
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uptake will be captured, as iron deficient women normally require four-six weeks to
return to pre-pregnancy iron levels using standard iron supplementation, as well as
capturing slower iron absorption that may occur during week three (Bodnar et al., 2002;
Hyder, Persson, Chowdhury, Lonnerdal, & Ekstrom, 2003).

Hypotheses Rationale
Hypothesis 1 predicts that iron rebound will occur in all three groups; this is because
postpartum iron status rebound is a normal occurrence and should be observed regardless
of participant supplement group (SickKids, 2009). One postulated benefit of placenta
ingestion relates to the organ’s iron content (Selander et al., 2013). It is proposed that the
bioavailability of iron found in placenta prepared in any form (e.g. raw, fried, baked,
grilled, blended, encapsulated, etc.) is superior to standard ferrous sulfate (iron)
supplementation. Ferrous sulfate is composed of non-heme iron, while the placenta
contains heme iron. The body absorbs heme iron two-three times more readily than nonheme iron (15-35% of heme iron versus 2-20% of nonheme iron) (Pavord et al., 2012;
Monson, 1988). The bioavailability of heme iron is generally not affected by other
dietary factors, while diet can greatly affect the bioavailability of non-heme iron (Pavord
et al., 2012; Young, et al., 2010). Meat of any form is a great source of heme iron and is
accounted for in this study, along with other impacting dietary factors. Foods high in
calcium can inhibit the bioavailability of both heme and nonheme iron. Phytates in
cereals, and the tannins found in coffee and tea can inhibit iron absorption of nonheme
iron. Eating foods with heme iron, as well as foods high in Vitamin C will enhance
nonheme iron absorption (Pavord et al., 2012).
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A majority of women engaging in placentophagy dehydrate, granulate, and
encapsulate their placenta, resulting in a supply of placenta supplements to be ingested
daily over a two to three week period, postpartum. One placenta encapsulation service
recommends taking two capsules three times per day for two weeks, with each capsule
containing 550 mg of dried placenta (PlacentaBenefits.info, 2015). One study has shown
that dietary iron in cooked beef reduces the bioavailability of heme iron from 65% in raw
beef, to 22% in beef cooked for 5.6 to 8.6 minutes. This study employed a fast, dry-heat
cooking method wherein meat was prepared in a Silex clam cooker set at 200 degrees
Celsius (392 degree Fahrenheit) (Purchas, Rutherford, Pearce, & Wilkinson, 2004).
Placenta pills are typically prepared using low-heat methods of steaming and dehydration,
which reach temperatures of 212 degrees Fahrenheit. As iron is a very heat-stable nutrient
and is not exposed to high temperatures during encapsulation, iron degradation is limited
with this method.
A recent study suggests that iron may have a significant effect upon women who
engage in maternal placentophagy. The study reveals that 96% of nearly 200 women who
had previously engaged in maternal placentophagy rated their experience as either “very
positive” or “positive,” 8% of participants listed restoring hormones/nutrients as a
motivating factor for engaging in placentophagy, and 26% of participants reported
increased energy, even though this was not a stated motivation for engaging in
placentophagy (Selander et al., 2013). This is noteworthy, given that energy is associated
with satisfactory iron stores, whereas iron deficiency is related to decreased energy, often
manifested as reduced work capacity (Haas & Browlie, 2001).
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CHAPTER 4

METHODS
Institutional Review Board and Institutional Biosafety Committee Approvals
This study was approved by UNLV’s Institutional Review Board (IRB) Institutional
Biosafety Committee (IBC). Active data collection for this study occurred between
December 2013 and March 2015. This research project was conducted in conjunction
with another study on the effects of human maternal placentophagy on postpartum
recovery wherein Experimental and Placebo Groups, as well as Iron Group data were
utilized for both studies.

Confidentiality
All information gathered in this study is kept as confidential as possible. All records
(biological samples and written data) are being stored in a locked facility at UNLV for
three years after completion of the study. Each participant was given a unique
alphanumeric ID code. Questionnaires and biological samples are stored independent
from the informed consent form to preserve confidentiality.

Participant Recruitment
Experimental and Placebo Groups
Participants were informed of the study by either the webpage or social media pages
for Placenta Benefits (PBi; an organization that provides placenta encapsulation
information and services), or by word of mouth through Jodi Selander, founder of PBi, or
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midwives and physicians with whom she works regularly. Interested women were
provided with contact information for a research team member who could then provide
more information and answer any questions about the study, and who could schedule the
first meeting with the research team.
Iron Group
Participants in the Iron Group were informed of the study by word of mouth, and
distribution of study fliers to various pregnancy and postpartum support groups in the Las
Vegas Valley (e.g. La Leche League, Well Rounded Momma, etc.). Flyer distribution did
not yield any responses, however word of mouth successfully found participants for the
Iron Group. All three participants in this group were women familiar with the
researchers; during the course of socializing, each participant was told about the study
and asked if they would like to participate.

Participants
In order to participate in this study, volunteers were screened for either the
Experimental and Placebo Groups, or the Iron Group. For the Experimental and Placebo
Groups, volunteers were required to be healthy, pregnant females over the age of 18 who
had decided to ingest their own placenta postpartum. Volunteers were excluded from
participating in this study if they had experienced any serious pregnancy complications,
ever ingested human placenta, or currently used drugs, cigarettes, or alcohol. Participants
who had any current or chronic health conditions, or who were taking medications during
pregnancy were required to discuss their decision to ingest their placenta postpartum with
their medical practitioner and to confirm that the practitioner had not advised against
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placentophagy in order to participate in the study. For the Iron Group, participants were
required to be healthy, pregnant females over the age of 18 who had decided not to ingest
their own placenta postpartum. Iron Group participants were excluded from participating
in this study if they had experienced any pregnancy complications, were planning to
ingest their placenta postpartum, currently used drugs, cigarettes, or alcohol, took any
medications, or had a medical condition that affects iron status (e.g., hemochromatosis,
thalassemia). Some participants had a medical condition that did not necessarily exclude
them from the study. In such cases, participants signed a form indicating they had spoken
with their medical doctor or midwife and that they were not advised against participating
in the study.

Procedures
Experimental and Placebo Groups
After the initial screening and providing informed consent, participants in the
Experimental and Placebo Groups met with two female research team members a total of
four times in the home of the participant or in a few select cases, in a secure lab on the
campus of UNLV.
The first meeting occurred during the 36th week of pregnancy where the participant
completed a background information questionnaire and provided a blood sample.
Approximately 600µl of blood was collected through a finger-stick blood draw into a
Sarstedt Multivette 600 capillary blood collection lithium heparin tube. An additional
30µl (15µl x 2 measurements) of this blood was collected onto a STAT-Site MHgb test
strip and placed in the STAT-Site MHgb meter for hemoglobin analysis. For biological
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sample collection, researchers wore the following personal protective equipment: gloves,
laboratory coat, and protective glasses.
The second meeting occurred within 96 hours postpartum where the participant’s
placenta was steamed, dehydrated, pulverized and encapsulated by a trained specialist,
and the participant provided a blood sample. At this meeting, participants were instructed
to ingest a postpartum supplement following a designated dosing schedule of two 550mg
capsules three times per day for days 1-4, two 550mg capsules two times per day for days
5-12, and two 550mg capsules once per day for days 13-21. The supplement was either
their own dehydrated and encapsulated placenta, or placebo capsules made of either
organic, grass-fed beef, or soy-free vegetarian meat substitute (Quorn Meatless & SoyFree Grounds). Prior to recruitment, identification codes were generated for each of the
anticipated participants in the Experimental and Placebo Groups and group assignments
were randomly generated for each participant using an online randomization generator
(http://www.randomization.com/). This was done by the Principle Investigator, Dr.
Daniel Benyshek, who also created sealed envelopes for each identification code that
indicated which treatment they would receive, and was opened by the encapsulation
specialist (Jodi Selander, Marcy Webb, or Romina Lizaso) after the placenta was
prepared, indicating to her whether to leave the placenta or placebo capsules with the
participant. Dr. Benyshek and the encapsulation specialists had no additional contact with
participants once the group assignment had been revealed. None of the research team
members who met with the participants throughout the study were aware of the
participant’s group assignment until the conclusion of that individual's participation.
Information about group assignment was maintained by Dr. Benyshek and was not
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accessible to other members of the research group. The assigned set of capsules (either
placenta or placebo) remained with the participant, while the second set was returned by
researchers to the lab at UNLV. A seal was created with a unique code sequence that
would be easily recognized by the participant, while simultaneously preserving their
anonymity, as this code was independent of the participant's ID code used for the study.
The label with the unique code was affixed over the lid of the jar of capsules that was
stored in the lab at UNLV. This was done in order to ensure that upon return of the
placenta capsules to a participant in the Placebo Group, she would be able to identify that
the capsules being returned were in fact her capsules. Labeled capsules were stored in a
locked freezer, in a locked laboratory, in a locked hallway at UNLV.
The third meeting occurred between the fifth and seventh day postpartum where the
participant completed a questionnaire about their dietary intake over the last year, and
provided a blood sample.
The fourth and final meeting occurred during the third week postpartum (days 21-27)
where participants provided a blood sample. At the conclusion of this meeting the
participant was debriefed and her group assignment was revealed. If she was in the
placebo group, her placenta capsules were returned to her at this time. Participants were
able to identify their capsules by the unique coded sticker affixed over the lid and written
in their handwriting.
Iron Group
Procedures for the Iron Group were identical to the Experimental and Placebo Group
with the exception of the following: during the second meeting (between day 5 and 7
postpartum), participants were instructed to ingest one 65 mg postpartum iron supplement
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(Nature’s Bounty 325 mg Ferrous Sulfate) once a day in the morning with a meal
(Stoltzfus & Dreyfuss, 1996; Hyder et al., 2003; Khalafallah & Dennis, 2012; Viteri &
Berger, 2005) for the duration of their participation in the study.

Compensation
Experimental and Placebo Groups
Direct interaction between study participants and researchers occurred over the course
of four separate occasions (approximately 60-90 minutes per meeting). Participants were
compensated for their time with an $80 gift card to their choice of Target or Whole Foods
at the conclusion of their participation in the study. To compensate participants for their
time at the third meeting, they were provided with their choice of the following:
housecleaning services, meal delivery, grocery delivery, doula services, or a consultation
with a lactation counselor. Additionally, placenta encapsulation services were provided at
no cost (approximate value of $300). When a participant withdrew prior to completion of
the study, they received compensation on a pro-rated basis based on the number of
meetings completed prior to withdrawal: a gift card in the amount of $20 per meeting
completed. Participants were provided with their encapsulated placenta if the placenta
had been processed prior to withdrawal. If withdrawal occurred after the third meeting,
the selected service was also provided.
Iron Group
As with the Experimental and Placebo Groups, direct interaction between Iron Group
participants and researchers occurred on four separate occasions (approximately 60
minutes per meeting). Participants were compensated for their time with an $80 gift card
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to their choice of Target or Whole Foods. No participants withdrew prior to the
completion of their participation in the study.

Questionnaires
A number of questionnaires were administered to evaluate changes in participants’
feelings and experiences during pregnancy and postpartum, and are included in the
broader study that evaluates the effects of placentophagy in postpartum women. The
Background Questionnaire was administered at Meeting 1 (see appendix), and the Willet
Food Frequency Questionnaire (FFQ) (Willet, et al., 1985) was administered at Meeting
3 (day five-seven postpartum) and collected at Meeting 4 (week three postpartum).
Willet Food Frequency Questionnaire
This questionnaire was administered to participants at the third meeting and collected
at the fourth meeting. The extensive nature and lack of temporal sensitivity of the Willet
FFQ compelled us to allow participants to complete the questionnaire at their leisure
between Meetings 3 and 4. The Willet FFQ averages the overall dietary intake of the
participant over the last year.
The iron content for each food item on the questionnaire was assessed in milligrams
and obtained from the USDA National Nutrient Database for Standard Reference Release
27 (United States Department of Agriculture, 2015). The most accurate and acceptable
food for each item was chosen. In some cases, multiple foods were listed for a single
entry (e.g. peach, apricot, or plum); in such cases, each item’s iron content was
investigated and the food item with the highest iron content and controlling for portion
size was chosen. It is important to note that dietary iron may be overcompensated using

!

25

this method. In a few rare cases, an item was not listed on the USDA Database. In such
cases, the search engine google.com was utilized to find an appropriate representation of
the item (e.g. the most popular or ubiquitous brand). For example, Coffee-Mate was
selected to represent non-dairy coffee whitener. When possible, unfortified foods were
chosen before fortified items. If a participant accidentally picked more than one
frequency for a food item, the more frequent option was chosen. If she failed to select a
frequency, the food was not included in the assessment.
The iron content for each supplement on the questionnaire was assessed in milligrams.
Using the specific supplement information obtained from the Willet FFQ and the
Background Questionnaire, exact supplementary iron intake was ascertained. In the few
cases where a participant failed to provide a frequency for a particular supplement, a
frequency of once per day was assumed. Utilizing these methods of assessment the
average daily iron intake of each participant was ascertained.
Frequencies in the Willet FFQ were provided to participants as a range; for the
purpose of accurate calculations, a single figure was chosen (e.g. 2-4 times per week
became 3 times per week). To calculate a daily dietary iron intake, a total annual dietary
iron intake was generated. The x amount of mg/Fe for each item was compared to its
ingestion frequency, and an annual figure was generated in this way. For example, one
egg contains 0.88 mg/Fe. The following is a formula for daily iron intake if a participant
consumes one egg once per week: (0.88 mg * 1 per week * 4 weeks * 13 months)/364
days = 0.12 mg/day. That participant, on average, receives 0.12 mg/day of iron from egg
consumption. Equations include 13 months (as opposed to 12) to account for the days in
excess of 28 missed every month using this formula. This provides an estimate up to 364
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days, just one day short of a year. Each item’s annual estimate was calculated in this
manner, and each item was combined for an annual iron consumption total for each
participant; that figure was then divided by 364 (days) in order to gain an average daily
iron ingestion estimate.
The Willet FFQ aids in accounting for iron fluctuations due to dietary factors
unrelated to iron, placenta, and placebo (beef or vegetarian) supplement ingestion.
Categorizing the iron intake of participants in this way allows these factors to be crossreferenced with biological assays (hemoglobin, transferrin, and ferritin levels measured in
participant blood and plasma), to assure that measured iron levels were not distorted by
dietary factors.
Iron intake status was assigned to one of three groups based upon iron Recommended
Dietary Intakes for lactating women between 19-50 years old (Trumbo, Yates, Schlicker,
& Poos, 2001). Participants under the daily Recommended Dietary Allowance of 9
mg/day were categorized as below, participants between 9-45 mg/day were categorized as
adequate, and participants exceeding the daily allowance of 45 mg/day were categorized
as exceeds.

Placenta and Placebo Supplement Processing and Encapsulation
Jodi Selander is the founder of the Las Vegas based organization Placenta Benefits,
LTD, a company that provides placenta encapsulation service to women in their own
home after giving birth. Selander, or one of her encapsulation specialists (Webb and
Lizaso), processed and encapsulated participants' placentas, in accordance with
Occupational Safety and Health Administration (OSHA) and Environmental Protection
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Agency (EPA) guidelines, in the home of the participant, using the Placenta Benefits
proprietary method in which the placenta is steamed with herbs, dehydrated, pulverized,
and encapsulated. The placenta was collected by the midwife or doctor at the birth and
left with the participant if she delivered at home, or transported to the home by the
participant if she delivered in a hospital. The encapsulation specialist met with the
participant in her home where she rinsed the organ with water, steamed it with herbs
added to the steaming water, and dehydrated the organ overnight. Once the placenta was
completely dehydrated, it was then pulverized using a food processor and plant-based,
non-gelatin capsules were filled with the dehydrated tissue to create the placenta capsules
that were given to the participant. The technique follows OSHA and EPA guidelines for
safe handling and disinfection and ensures that the placenta did not come into contact
with another individual's placenta, as each placenta was processed and prepared in the
participant's home using sanitized equipment.
The placebo capsules were prepared by a research team member, Sharon Young, at
UNLV following identical methods to the processing and encapsulation of the placenta,
with the exception of using herbs in the steaming water. Placebo capsules were prepared
using either organic, free-range beef or a soy-free vegetarian ground beef substitute
(Quorn brand Meatless & Soy-Free Grounds). Organic, free-range beef was used in order
to reduce the presence of exogenous hormones in the meat-based placebo supplement,
while maintaining a consistency that is similar to that of the placenta capsules. The
vegetarian option was offered for participants who practiced a vegetarian diet or preferred
a supplement that was not beef-based, and the meatless ground beef substitute was
selected as the vegetarian option in order to maintain a similar consistency to that of the
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placenta capsules. Three participants chose the vegetarian placebo, while the remainder
(n=13) chose the beef placebo.

Assessment of Iron Status
Iron status was assessed via hemoglobin, transferrin, and ferritin levels in participant
blood samples (Santo, 2012; Denic & Agarwal, 2007; Khalafallah & Dennis, 2012).
Blood samples were typically collected in the late morning toward the end of each
meeting, however the timing of sample collection varied for some participants. Blood
samples were collected in the evening for three meetings (twice for one participant, once
for another participant), and several samples were collected in the early morning or early
afternoon.
Some studies have shown that blood samples collected via capillary action
overestimate hemoglobin levels in the high range and underestimate hemoglobin levels in
the low range, when compared to standard venous samples (Cable, et al., 2012). Other
studies show more generally that capillary hemoglobin values are greater than venous
levels (Patel, Wesley, Leitman, & Bryant, 2013). For this study, our use of the point of
care (POC) tool, STAT-Site hemoglobin meter, prevents us from encountering this issue
for hemoglobin. Expected Values for this POC instrument establish the expected values
for adult females as 11.0-18.0 g/dL (Stanbio Laboratory, 2013). Hemoglobin was
measured onsite using the portable STAT-Site MHgb meter, which has a total precision
coefficient of variation (CV) of 2.9% - 4.2%, and a within run precision CV of 3.5% 4.9% (Stanbio Laboratory, 2012). In the majority of cases, two blood spots were
collected allowing us to calculate an average. In some cases the figures varied, but this
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was normally due to collection error wherein drops of blood did not both meet the
recommended 12µL required for the meter. Reference value ranges for this project are
based upon the STAT-Site hemoglobin Expected Values of 11-18 g/dL.
ZRT Laboratory (Beaverton, Oregon) analyzed transferrin and ferritin via
immunoassay of plasma taken from finger-stick capillary samples. Siemens ELISA kits
for transferrin and ferritin were used, with the following expected values: transferrin:
202-364 mg/dL, and ferritin (Women 17-60 years): 13-150 mg/mL (Aquilani, et al.,
2014; Eaton, 2013). The threshold values used in this analysis for transferrin and ferritin
are based upon venous blood samples rather than capillary blood samples (capillary being
the method of collection used in this study). For the purposes of this study we are
comparing between groups, therefore minor (3-7%) fluctuations of the exact values will
not affect the comparisons made (Mejia & Viteri, 1983; Lu, Lynch, Cook, Madan, &
Bayer, 1987).

Statistical Measures
Using SPSS version 21, the following statistical measures were conducted: Mixed
ANOVA, with sphericity adjustment where necessary (e.g., the Greenhouse-Geisser
estimate), tested within- and between-subjects factors simultaneously. Mixed ANOVAs
were also conducted controlling for dietary iron status (i.e., based on categories below,
adequate or exceeds recommended intake).
Pearson’s r calculated correlations among dependent variables (i.e. hemoglobin,
transferrin, and ferritin) within each time period (Meetings 1 through 4). Fluctuations
were analyzed within the Experimental Group and the Placenta Group and then compared
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between groups. Given the small sample size of the Iron Group (n=3), data for that
condition are assessed as a case study, as they cannot be statistically evaluated alongside
Experimental and Placebo Group data.
For the small number of data points missing, data from a participant’s previous time
period were carried forward to fill in missing data (i.e. Meeting 2 for participant PL-1012,
and Meeting 4 for participant PL-1017).
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CHAPTER 5

RESULTS
Initial recruitment of the study had three participants in the Iron Group and 36
participants in the Experimental and Placebo Groups. Eight participants withdrew or were
dropped from the study, and one participant switched from the Experimental and Placebo
Group to the Iron Group after the first meeting. Only one participant withdrew from the
study after initiation of supplementation, due to fear of a bad reaction to the placenta
capsules (e.g. participant felt weepy and hormonal), however after withdrawal, it was
discovered that she was a participant in the Placebo Group. This means that there was no
group-based bias in dropouts due to placenta or placebo ingestion.
The following is a breakdown of participants included in final analyses for each test
group: (1) Experimental Group: (n=12), and (2) Placebo Group: (n=16). Iron Group
(n=3) will be examined separately.

Participant Demographics
The women who participated in this study were an average age of 30 years old, with
the majority Caucasian (77.4%). Most participants had an education of at least some
college or more (83.9%); with almost equal amounts of women having attended some
college, and earning Bachelors and Masters degrees. Fifty-five point two percent had a
household income of at least $50,000 a year; 17.2% of participants earned between
$20,000 and $30,000 (the lowest household income bracket selected by participants).
According to a 2014 Demographic Report, the median household income for Las Vegas
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was $45,670, and $47,270 for Clark County, Nevada (City of Las Vegas Economic and
Urban Development Department & Redevelopment Agency, 2014). The majority of
participants were married or in a domestic partnership (87%) (see Table 1). The
demographic profile of participants in the current study is largely consistent with that of
other published studies of women who have engaged in maternal placentophagy in the
past (Selander et al., 2013).

Demographic Characteristics
Frequency %
Age (N = 31; mean = 30)
Ethnicity (N = 31)
African American
Caucasian
Hispanic/Latina
Mixed: American Indian/Alaska
Native, Caucasian
Education (N = 31)
High School or equivalent
Vocational/technical school
Some college
Bachelor's degree
Master's degree
Doctoral degree
Household Income (N = 29)
$20,001 - 30,000
$30,001 - 40,000
$40,001 - 50,000
$50,001 - 60,000
$60,001 - 70,000
$70,001 - 80,000
Over $80,000
Marital Status (N = 31)
Single, never married
Married or domestic partnership
Divorced
Table 1: Demographic Characteristics
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2
24
4

6.5%
77.4%
12.9%

1

3.2%

1
4
9
8
8
1

3.2%
12.9%
29.0%
25.8%
25.8%
3.2%

5
5
3
2
3
2
9

17.2%
17.2%
10.3%
6.9%
10.3%
6.9%
31.0%

3
27
1

9.6%
87.0%
3.2%

Dietary Iron RDA at Meeting One
Recall that the potential impact of dietary iron unrelated to capsule ingestion upon iron
status is controlled for via the Willet FFQ. Participants generally split evenly into one of
two categories: adequate or exceeds RDA for lactating women (9mg/day), with only one
participant below RDA. However, 9mg/day is much lower than the recommendations for
pregnant women of 27 mg/day (Khalafallah & Dennis, 2012). For this reason it was
important to determine the annual average dietary iron intake of participants during week
36 of pregnancy (Meeting 1) based upon the recommended daily allowance for pregnant
women. Table 2 shows that an additional three participants were below RDA for pregnant
women, splitting almost evenly among the three conditions: Experimental, Placebo, and
Iron Groups.

Week 36 of Pregnancy (Meeting 1)
RDA for pregnant women (27 mg/day)
Experimental
(Placenta)
Group
Placebo Group Iron Group
Below
(<27 mg/day)
Adequate
(27-45 mg/day)
Exceeds
(>45mg/day)
Total

Total

1

2

1

4

5

4

1

10

5

10

1

16

n = 11*

n = 16

n=3

n = 30

Table 2: Week 36 of Pregnancy (Meeting 1): RDA for pregnant women (27 mg/day)
*One participant from the Experimental Group did not complete the Willet FFQ.

Iron Status Analytes
The reference ranges for each iron analyte (hemoglobin, transferrin, and ferritin
respectively) are examined below, separated according to participant condition:
Experimental (Placenta) Group, Placebo Group, and Iron Group. Reference ranges
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classify participants into three analyte status categories: below, expected, and exceeds
reference range (see Table 3). It is important to note that these categories do not represent
‘iron deficient’ clinical diagnosis categories in the context of this study. Such diagnoses
should only be made by a licensed health care provider using standardized clinical
procedures and laboratory methods. Rather, these categories are presented here for
heuristic and comparative purposes only – based on manufacturer POC meter and
laboratory assay reference ranges. For hemoglobin ranges, recall that the STAT-Site Hgb
Meter expected values for adult females are 11.0-18.0 g/dL (Stanbio Laboratory, 2013).
Expected transferrin values range between 202-364 mg/dL, with levels greater than 364
indicating transferrin deficiency and levels lower than 202 indicating transferrin excess
(Aquilani, et al., 2014). Expected ferritin values for women 17-60 years are 13-150
mg/mL (Eaton, 2013).

HGB
Below

Transferrin

Ferritin

<11 g/dL

>364 mg/dL

<13 ng/mL

Expected

11-18 g/dL

202-364 mg/dL

13-150 ng/mL

Exceeds

>18 g/dL

<202 mg/dL

>150 ng/mL

Table 3: Expected Ranges for Iron Analytes

Figures 1-3 categorize the Experimental (Placenta) Group (n=12), the Placebo Group
(n=16), and the Iron Group (n=3) by hemoglobin, transferrin, and ferritin expected values
(below and expected), as well as provide the number of participants for each expected
value category and meeting. Tables 4-6 provide us with additional information on

!

35

averages for each meeting, subdivided by the status of the analyte (below, expected, and
exceeds). Please note that no participant hemoglobin samples exceeded expected values,
and therefore the exceeds category was not included in Figure 1 and Table 4.
Hemoglobin
From the data in Figure 1 and Table 4, we can see that below participants in the
Experimental (Placebo) Group increase from Meeting 1 to 2. Following placenta
supplement initiation, below values decrease across the next two meetings. No participant
hemoglobin levels fall within the exceeds range for the Experimental Group.
Participants from The Placebo Group with values below the reference range increase
from Meeting 1 (two participants) to Meeting 2 (nine participants). Following placebo
supplement initiation, values below the reference range decrease to one participant at
Meeting 3, and zero participants at Meeting 4. No participant hemoglobin ranges fall
within the exceeds range for this Placebo Group.
All three participants from the Iron Group are within the expected hemoglobin range
over the course of the four meetings, with no participants experiencing below or exceeds
hemoglobin
Transferrin
For all three groups (Experimental, Placebo, and Iron) we can see that participants
with values below the reference range decrease across the four meetings, participants
with values in the expected reference range increases across the four meetings, and only
two participants from the Placebo Group exceeds transferrin at Meeting 4 (Figure 2 and
Table 5).
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Ferritin
For all three groups, Figure 3 and Table 6 show that participants with ferritin values
below the reference range generally decrease across all four meetings, excluding a slight
uptick of one participant at Meeting 4 for the Experimental Group. The Iron Group had a
single case of ferritin values below the reference range at Meeting 1, which resolved
thereafter. The number of participants within the expected range generally increases
across meetings for all groups; once again, however, the Experimental Group has a
decrease by one participant from Meeting 3 (ten participants) to Meeting 4 (nine
participants). Only one participant (PL-1032, from the Placebo Group) recorded an
exceeds value for transferrin, which occurs across all four meetings.
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Number of Participants

Hemoglobin
20

14 15

15
9

10
5

3

65

67

9

3

9

16

7

Meeting 1
3333

2 1
0

0000

below expected

below expected

below expected

Experimental
(Placenta)
n=12

Placebo
n=16

Iron
n=3

0

Meeting 2
Meeting 3
Meeting 4

Figure 1: Number of participants with hemoglobin levels in below and expected ranges, broken up by
Condition. Note that no participant hemoglobin samples exceeded the expected range.

Hemoglobin
Analyte
Group
Status
Experimental below
(Placenta)
expected
below
Placebo
expected
below
Iron
expected

Meeting 1 Meeting 2 Meeting 3
Meeting 4
N
Mean N Mean N
Mean N
Mean
3 10.38 6
8.88
5
9.44
3
9.53
9 12.38 6 11.65
7 12.62
9 13.34
2
9.05 9 10.41
1 10.85
0
N/A
14 12.65 7 12.50
15 12.77 16 13.45
0
N/A 0
N/A
0
N/A
0
N/A
3 11.98 3 12.33
3 12.75
3 12.50

Table 4: Number of participants and means of hemoglobin levels in below and expected ranges,
broken up by Condition. Note that no participant hemoglobin samples exceeded the expected range.
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Experimental
(Placenta)
n=12

Placebo
n=16

exceeds

0

expected

2 211 1223
000
0
0000
exceeds

0000

5
3
3

expected

4 3 8
42

below

10

below

8

1314
11
13

exceeds

9

expected

16
14
12
10
8
6
4
2
0

below

Number of Participants

Transferrin

Meeting 1
Meeting 2
Meeting 3
Meeting 4

Iron
n=3

Figure 2: Number of participants with transferrin levels in below, expected, and exceeds ranges,
broken up by Condition.

Transferrin
Group

Analyte
Status
below
Experimental
expected
(Placenta)
exceeds
below
Placebo
expected
exceeds
below
Iron
expected
exceeds

Meeting 1 Meeting 2
Meeting 3
Meeting 4
N Mean N
Mean N Mean
N Mean
9 416.33
4 414.25
4 409.50
2 393.00
3 352.66
8 333.75
8 327.75 10 281.60
0
N/A
0
N/A
0
N/A
0
N/A
5 435.60
3 420.00
3 408.66
0
N/A
11 329.09 13 303.61 13 295.38 14 272.57
0
N/A
0
N/A
0
N/A
2 188.50
2 485.50
1 510.00
1 511.00
0
N/A
1 347.00
2 317.00
2 309.50
3 278.33
0
N/A
0
N/A
0
N/A
0
N/A

Table 5: Number of participants and means of transferrin levels in below, expected, and exceeds
ranges, broken up by Condition.
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14
13
10
9
8
9

10
14
5

Meeting 1

Experimental
(Placenta)
n=12

Placebo
n=16

000

Meeting 2
0000

Meeting 3

exceeds

expected

exceeds

11
below

exceeds

0000

1111 1

333
2
expected

2

below

4
3 3
2
expected

16
14
12
10
8
6
4
2
0

below

Number of Participants

Ferritin

Meeting 4

Iron
n=3

Figure 3: Number of participants with ferritin levels in below, expected, and exceeds ranges, broken
up by Condition.

Ferritin
Group

Analyte
Status
below
Experimental
expected
(Placenta)
exceeds
below
Placebo
expected
exceeds
below
Iron
expected
exceeds

Meeting 1
Meeting 2
Meeting 3
Meeting 4
N
Mean N
Mean
N
Mean
N
Mean
4
6.67
3
7.35
2
6.17
3
6.93
8
25.67
9
55.53 10
51.18
9
66.44
0
N/A
0
N/A
0
N/A
0
N/A
5
8.60
2
9.11
1
8.89
1
12.00
10
23.45 13
40.02 14
41.12
14
54.46
1 160.00
1 236.00
1 347.00
1
289.00
1
7.86
0
N/A
0
N/A
0
N/A
2
21.68
3
39.63
3
48.73
3
67.26
0
N/A
0
N/A
0
N/A
0
N/A

Table 6: Number of participants and means of ferritin levels in below, expected, and exceeds ranges,
broken up by Condition.
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Deficiencies of Multiple Analytes at Corresponding Time Points
Table 7 supplies a breakdown of participants who recorded sample values below the
expected reference range for more than one analyte at corresponding time points. The
Experimental (Placenta) Group had a greater amount of participants that began with
values below the expected reference range for multiple analytes than did the
Experimental (Placenta) Group. Twenty-five percent of Experimental Group participants
were below the expected reference range in two out of three analytes at Meeting 1,
compared to 13% of Placebo Group Participants. While 33% of Iron Group participants
were below the expected reference range in two out of three analytes at Meeting 1, it is
important to note that this percentage comprises a single participant (with a total of three
Iron Group participants), and making comparisons to the other larger groups difficult.
Seventeen percent of Experimental (Placenta) Group participants were below the
expected reference range in three out of three analytes at Meeting 1, compared to 6% of
Placebo Group Participants, and 0% of Iron Group participants.
This initial disparity in iron analytes among groups will be important when further
analyzing our results.
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Meeting 1

Total Group N

Analytes:
Hemoglobin,
Transferrin,
Ferritin
N = 12 Experimental
(Placenta)
Group N
Experimental
(Placenta)
Group
Percentage
N = 16 Placebo Group
N
Placebo Group
Percentage
N = 3 Iron Group N
Iron Group
Percentage

Meeting 2

Meeting 3

Meeting 4

Number of values below the expected reference range
2 of 3

3 of 3

2 of 3

3 of 3

2 of 3

3 of 3

2 of 3

3 of 3

3

2

1

2

1

2

0

2

25%

17%

8%

17%

8%

17%

0%

17%

2

1

1

1

0

0

0

0

13%
1

6%
0

6%
0

6%
0

0%
0

0%
0

0%
0

0%
0

33%

0%

0%

0%

0%

0%

0%

0%

Table 7: Participants with sample values below the expected reference range for 2 of 3, or 3 of 3
analytes at corresponding time points.
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The following three sections analyze iron levels assessed via hemoglobin, transferrin,
and ferritin, whereas above, participants were separated into dietary iron status groups.

Hemoglobin Results
Analysis of hemoglobin data for Experimental (Placenta) and Placebo Groups, not
controlling for dietary iron status, showed a statistically significant (p=0.000) change
over time (Figure 4). There was a decrease in hemoglobin at Meeting 2, followed by an
improvement in hemoglobin at Meeting 3 and a further improvement at Meeting 4.
Hemoglobin pairwise comparisons for the Experimental Group using Bonferroni
corrected post hoc tests show there were statistically significant differences between
Meetings: 1 to 2 (p=0.048), 2 to 3 (p=0.005), 2 to 4 (p=0.000), and 3 to 4 (p=0.001).
Likewise, hemoglobin pairwise comparisons for the Placebo Group using Bonferroni
corrected post hoc tests show there were statistically significant differences between
measures: 2 to 3 (p=0.001), and 2 to 4 (p=0.000).
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Figure 4: Hemoglobin boxplots comparing Experimental (Placenta) Group and Placebo Group
across meetings 1-4.

However, the interaction of hemoglobin and condition was not significant (p=0.276).
In other words, the hemoglobin of Experimental and Placebo Groups changed over time,
but changed in similar ways. Figure 5 shows the parallel movement of hemoglobin status
over time. We see that the groups have parallel lines that decrease from Meetings 1 to 2,
and then increase steadily afterward (indicating hemoglobin status improvement).
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Figure 5: Hemoglobin Estimated Marginal Means comparing Experimental (Placenta) Group and
Placebo Group across meetings 1-4.

The difference in mean hemoglobin values between the Experimental and Placebo
Groups at any time point simply represents the different average baseline levels for the
two groups. In addition, between-subjects effects show that the average difference
between Experimental and Placebo Groups was not statistically significant (p=0.059).
The majority of Experimental and Placebo Group participants were grouped into
adequate dietary iron status or exceeds RDA recommendations for iron intake among
lactating women (19 – 50 y) based upon the results of their Willet FFQ responses. Eleven
participants had a daily average iron intake between 9-45 mg/day, or adequate dietary
iron intake. Fifteen participants had a daily average iron intake over 45 mg/day, or
exceeds dietary iron intake. Four participants fell below the RDA iron intake
recommendations (Table 2). A Mixed ANOVA was completed controlling for these
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dietary groups, with no statistical differences shown between dietary controls and the
hemoglobin results.

Transferrin Results
Analysis of transferrin data for Experimental (Placenta) and Placebo Groups, not
controlling for dietary iron status, showed a statistically significant (p=0.000) change
over time (Figure 6). There was a steady improvement of iron status as estimated from
plasma transferrin, over time (note that lowering transferrin levels indicate improved iron
status).
Transferrin pairwise comparisons for the Experimental Group using Bonferroni
corrected post hoc tests show there were statistically significant differences between
Meetings: 1 to 3 (p=0.04), 1 to 4 (p=0.000), 2 to 4 (p=0.005), and 3 to 4 (p=0.001).
Transferrin pairwise comparisons for the Placebo Group using Bonferroni corrected post
hoc tests show there were statistically significant differences between measures: 1 to 2
(p=0.002), 1 to 3 (p=0.000), 1 to 4 (p=0.000), 2 to 4 (p=0.000), and 3 to 4 (p=0.000).
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Figure 6: Transferrin boxplots comparing Experimental (Placenta) Group and Placebo Group across
meetings 1-4.

The interaction of transferrin and condition was not significant (p=0.986). As with
hemoglobin, the transferrin values of Experimental and Placebo Groups changed over
time, but changed in similar ways. Figure 7 shows the parallel movement of transferrin
status over time. We see that the groups have parallel lines that decrease steadily through
Meetings 1 to 4 (indicating transferrin status improvement). Once again, differences in
transferrin values for the Experimental and Placebo Groups reflected different baseline
levels which were not affected by either the experimental or placebo conditions.
Between-subjects effects show that the average difference between Experimental and
Placebo Groups was not statistically significant (p=0.052).
As with hemoglobin, a Mixed ANOVA was used to control for iron dietary groups
(adequate and exceeds). There was only one difference shown between transferrin (n=28),
!
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and transferrin_adequate (n=11). The between-groups test for transferrin of all dietary
groups indicates that the variable condition (Experimental vs. Placebo) is not significant
(p=0.052), consequently, in Figure 7 we see that the lines for the two groups are close
together. The between-groups test for transferrin_adequate indicates that the
variable condition (Experimental vs. Placebo) is significant (p=0.037), consequently in
Figure 8 we see that the lines for the two groups are a bit apart (especially in comparison
to Figure 7). This means that transferrin_adequate conditions (Experimental and Placebo)
started off at statistically significant different points. Recall that Mixed ANOVAs showed
no statistical differences between dietary controls and hemoglobin results. This
underlines the importance of assessing multiple analytes (in this study: hemoglobin,
transferrin, and ferritin) to garner a more accurate understanding of iron status.
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Figure 7: Transferrin Estimated Marginal Means comparing Experimental (Placenta) Group and
Placebo Group across meetings 1-4, for all dietary transferrin groups (n=28).
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Figure 8: Transferrin Estimated Marginal Means comparing Experimental (Placenta) Group and
Placebo Group across meetings 1-4, for Adequate Dietary Group (n=11)
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Ferritin Results
Analysis of ferritin data for Experimental (Placenta) and Placebo Groups, not
controlling for dietary iron status, required a Log10 transformation to normalize the data.
Figure 9 shows the ferritin boxplots prior to Log10 transformation, and Figure 10 shows
the normalized data.

Figure 9: Ferritin boxplots comparing Experimental (Placenta) Group and Placebo Group across
meetings 1-4, prior to Log10 transform.
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Figure 10: Ferritin boxplots comparing Experimental (Placenta) Group and Placebo Group across
meetings 1-4, after Log10 transform.

Normalized ferritin data reveals a statistically significant (p=0.000) change (Figure
10). There was a steady increase of ferritin over time, indicating improved iron status.
However, the interaction of ferritin and condition was not significant (p=0.751). As with
the two other biomarkers for iron status in the study, ferritin of Experimental and Placebo
Groups changed over time, but changed in similar ways. Figure 11 shows the parallel
movement of ferritin status. We see that the groups have parallel lines that increase
steadily from Meetings 1 to 4 (indicating ferritin status improvement). In addition,
between-subjects effects reveal that the average difference in ferritin values between
Experimental and Placebo Groups was not statistically significant (p=0.357).
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Figure 11: Ferritin Estimated Marginal Means comparing Experimental (Placenta) Group and
Placebo Group across meetings 1-4.

Ferritin pairwise comparisons for the Experimental Group using Bonferroni corrected
post hoc tests show there were statistically significant differences between Meetings: 1 to
2 (p=0.026), and 1 to 3 (p=0.003). Pairwise comparisons for the Placebo Group using
Bonferroni corrected post hoc tests show there were statistically significant differences
between Meetings: 1 to 2 (p=0.000), 1 to 3 (p=0.000), and 1 to 4 (p=0.000).
Once again, a Mixed ANOVA was used to control for iron dietary groups (adequate
and exceeds). No statistical differences were shown between iron dietary groups and
overall ferritin results.
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Pearson’s r Correlation
Pearson’s r Correlation was utilized to calculate correlations among variables within
each time period. The following are statistically significant (p<0.10) correlations from
both conditions (Experimental and Placebo Groups), broken up by meeting time.

Meeting 1

Experimental
(Placenta)

Transferrin to Ferritin
Effect
p-value
Strong,
negative
0.015
(r = -0.680)

Hemoglobin to Ferritin
Effect
p-value

Positive,
moderate
(r = 0.533)

Placebo

0.033

Table 8: Meeting 1 Pearson’s r Correlation by Condition

Meeting 2

Experimental
(Placenta)
Placebo

Transferrin to Ferritin
Effect
p-value
Negative,
strong
0.004
(-0.762)
Negative,
moderate
0.081
(-0.449),

Table 9: Meeting 2 Pearson’s r Correlation by Condition

Experimental
(Placenta)
Placebo

Meeting 3
Transferrin to
Transferrin to Ferritin
Hemoglobin
Effect
p-value
Effect
p-value
Negative,
Positive,
strong
0.001
strong
0.018
(-0.837)
(0.667)
Negative,
strong
0.016
(-0.589)

Table 10: Meeting 3 Pearson’s r Correlation by Condition
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Hemoglobin to
Ferritin
Effect
p-value

Positive,
moderate
(0.495)

0.051

Meeting 4
Transferrin to
Transferrin to Ferritin
Hemoglobin
Effect
p-value
Effect
p-value
Negative,
Negative,
Experimental
strong
0.000
strong
0.001
(Placenta)
(-0.868),
(-0.821)
Negative,
Placebo
strong
0.021
(-0.572),

Hemoglobin to
Ferritin
Effect
p-value
Positive,
strong
0.002
(0.799),

Table 11: Meeting 4 Pearson’s r Correlation by Condition

Analytes from Meetings 2 through 4 correlate similarly across conditions. The effect
size and correlation of transferrin to ferritin is similar for each condition: negatively
correlated with a moderate to strong effect. As transferrin decreases, ferritin increases.
This makes sense, as transferrin will lower and ferritin will rise with improved iron status.
This is further indication that a great deal of difference between Experimental and
Placebo Groups may not exist.

Iron Group
The small sample size (n=3) of the Iron Group will not enable comparative statistical
analyses to be conducted with the Experimental and Placebo Groups. Instead, descriptive
statistics for this data are examined to garner a general idea of Iron Group results and
how they might compare given a more robust sample size.
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Hemoglobin
14
13.5

Iron Mean

13
g/dL

12.5

Placenta Mean

12
Placebo Mean

11.5
11

<11

10.5

Below Expected
Reference Range

10
Meeting 1 Meeting 2 Meeting 3 Meeting 4
Figure 12: Hemoglobin means for meetings 1-4 by Condition.

Condition
Iron
Placenta
Placebo

Meeting 1
Mean
SD
11.98
0.80
11.88
1.11
12.20
1.79

Hemoglobin
Meeting 2
Mean
SD
12.33
0.93
10.27
1.84
11.33
1.17

Meeting 3
Mean
SD
12.75
1.00
11.29
2.11
12.66
1.20

Meeting 4
Mean
SD
12.50
0.93
12.39
1.97
13.45
0.90

Table 12: Hemoglobin means and Standard Deviations for meetings 1-4 by Condition.

Transferrin
500
450

Iron Mean

mg/dL

400
>364

350

Placenta Mean
Placebo Mean

300

Below Expected
Reference Range

250
200
Meeting 1 Meeting 2 Meeting 3 Meeting 4

Figure 13: Transferrin means for meetings 1-4 by Condition. Note that transferrin deficiency is
indicated by greater than values.
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Condition
Iron
Placenta
Placebo

Meeting 1
Mean
SD
439.33 129.20
400.42 49.65
362.37 62.60

Transferrin
Meeting 2
Mean
SD
381.33 113.00
362.00 52.00
325.44 58.40

Meeting 3
Mean
SD
376.67 118.00
355.00 51.60
316.62 56.20

Meeting 4
Mean
SD
278.33 57.18
300.16 51.71
262.06 46.02

Table 13: Transferrin means and Standard Deviations for meetings 1-4 by Condition.

Ferritin
80
70
Iron Mean

ng/mL

60
50

Placenta Mean

40
Placebo Mean

30
20
<13

10

Below Expected
Reference Range

0
Meeting 1 Meeting 2 Meeting 3 Meeting 4
Figure 14: Ferritin means for meetings 1-4 by Condition.

Condition
Iron
Placenta
Placebo

Meeting 1
Mean
SD
17.08
14.68
19.34
14.75
27.34
36.52

Ferritin
Meeting 2
Mean
SD
39.63
25.00
46.05
40.70
48.41
52.60

Meeting 3
Mean
SD
48.73
17.40
43.68
35.10
58.23
78.40

Meeting 4
Mean
SD
67.26
61.36
51.57
47.00
66.47
66.82

Table 14: Ferritin means and Standard Deviations for meetings 1-4 by Condition.

For the Iron Group, excluding hemoglobin, the means of transferrin and ferritin for
each meeting generally trend the same as the Experimental Group and the Placebo Group.
Due to the Iron Group’s small sample size, it is not possible to draw any conclusions
based on statistical analysis. However, from these iron supplement group comparisons,
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the data are consistent with this study’s null hypotheses (1a, 1b, and 1c), that the
Experimental Group would not show a greater interval increase in iron levels (assessed
via hemoglobin, transferrin, and ferritin) as compared to Placebo and Iron Group
participants from: (1a) baseline (within 72 hours postpartum) to day five-seven
postpartum, (1b) baseline to week three postpartum, and (1c) days five-seven postpartum
to week three postpartum.
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CHAPTER 6

DISCUSSION
Hypotheses Revisited
Hypothesis 1: Supported
Experimental, Placebo, and Iron Group participants showed an increase in iron
levels (assessed via hemoglobin, transferrin, and ferritin) measured during, (a) days fiveseven postpartum, and (b) week three postpartum, as compared to baseline measure
taken prior to supplement initiation (within 72 hours postpartum).
Hypothesis 1a: Rejected
Experimental Group participants did not show a greater interval increase in iron
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group
and Iron Group participants from baseline (within 72 hours postpartum) to day fiveseven postpartum.
Hypothesis 1b: Rejected
Experimental Group participants did not show a greater interval increase in iron
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group
and Iron Group participants from baseline to week three postpartum.
Hypothesis 1c: Rejected
Experimental Group participants did not show a greater interval increase in iron
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group
and Iron Group participants from days five-seven postpartum to week three postpartum.
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Data analyses support Hypothesis 1 and fail to support the Null Hypothesis. The
statistical analyses conducted to test Hypotheses 1a, 1b, and 1c support the Null
Hypotheses and fail to support Hypotheses 1a, 1b, and 1c. The Iron Group failed to
recruit a sufficient amount of participants to address this group’s role in Hypotheses 1a,
1b, and 1c via statistical analysis.

Public Health Implications
Placentophagy is a growing practice in the Las Vegas Valley and has been spreading
within industrialized countries since the 1960s (Young & Benyshek, 2010). High profile
celebrities are engaging in this practice, and television programs have featured
placentophagy, thereby increasing its public visibility and introducing millions of women
to a practice that has not been subjected to rigorous scientific evaluation with respect to
its potential health benefits and/or risks.
If some women forgo traditional postpartum iron supplementation in favor of
placenta supplementation, it is necessary that any iron present in those supplements be in
a bioavailable form and in sufficient amounts to meet the increased iron demands
associated with pregnancy and nursing. Iron deficiency and IDA are associated with
negative health outcomes for both mother and child, making this issue particularly
important. Unfortunately, this study was not able to assess the effect of encapsulated
placenta supplementation on the iron status of postpartum mothers suffering from
clinically diagnosed iron deficiency or IDA. The current study’s results do suggest,
however, that encapsulated placenta supplementation neither significantly improves, nor
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significantly impairs postpartum maternal iron status for women consuming at least
adequate amounts of dietary iron postpartum1.

Limitations
Given the recruitment limitations associated with a double-blind placebo-controlled
study centered upon the ingestion of a participant’s own placenta, the participant sample
was, as a matter of necessity, self-selecting; not every pregnant women will want to
ingest their placenta postpartum. Therefore, the Experimental and Placebo Groups used
in this study consisted of a self-selecting population, making true randomization
impossible.
Samples sizes for Experimental and Placebo Groups could have been more robust,
however the sample sizes were large enough to conduct statistical analyses and draw
conclusions about differences and similarities between the two groups. The Iron Group’s
low sample size (n=3) prevented similar statistical comparisons among all three groups.
Instead, Iron Group data were examined as case studies. Due to this we were unable to
address portions of this study’s research questions related to the efficacy of placenta
supplementation in comparison to standard iron supplements regarding recovery from
postpartum iron deficiency.
The gold-standard for hemoglobin measurement is the direct cyanmethaemoglobin
method analyzed via spectrophotometer. This method, however, requires processing of
samples within a few hours of collection as well as access to an appropriately equipped
laboratory (Sari, et al., 2001). Given these constraints, the POC STAT-Site Hemoglobin
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1!Only one participant from our sample had an average daily dietary intake of iron below
RDA recommendations during lactation.!
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Meter is an excellent alternative. POC tools are essential for immediate bedside care of
patients, and are extremely convenient when used to conduct medical anthropological
field research. The accuracy of the STAT-Site Hemoglobin meter is dependent upon the
use of blood drops of a particular volume, however. The STAT-Site meter will give
erroneous results for drops smaller than 10µL and larger than 30µL (Stanbio Laboratory,
2013). Both slight variation in blood collection technique among project researchers, and
variation in the hydration of participants effecting ease of blood flow may lead to
differences in the size of blood drops collected and therefore hemoglobin results. In order
to reduce this error, whenever possible, two drops were collected and averaged.
For this study, blood samples were collected via finger-stick lancet. Generally,
venous blood draws are a more commonly used collection method, and most ranges for
analytes are based upon venous blood as opposed to finger-stick capillary blood samples.
As mentioned in Chapter 4, capillary blood differs from venous blood in a number of
ways and affects some, but not all, analytes. In the case of this study, ranges for expected
hemoglobin status were included with the STAT-Site Hemoglobin meter, which are
already adapted for capillary blood samples. Transferrin and ferritin ranges, however, are
not adapted to the collection method used in this study. Lu et al. (1987) reports that
capillary ferritin values may be about 7% higher than venous values. Another study
shows that capillary plasma overestimates ferritin by 8.9% in adults when compared to
venous plasma (Mejia & Viteri, 1983). All blood samples from this study were collected
via finger-stick capillary method. Given that iron status was not included in the
participant selection criteria, and that one of the primary goals of this study was to make
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relative comparisons between groups, obtaining laboratory values precise enough for
diagnostic purposes (e.g., IDA), were not necessary.
Some methods used to analyze data gathered from the Willet FFQ favored the
possibility of overestimation of participant dietary iron status. For example, some
questions on the Willet FFQ presented participants with a selection of similar foods, but
required a single answer for that grouping; one entry asked the frequency of consumption
of peaches, apricots, or plums. In cases such as these, each item’s iron content was
investigated using the USDA National Nutrient Database. The food item with the highest
iron content, controlling for portion size, was always chosen. The use of such methods
may lead to the overcompensation of dietary iron, however, it is preferable to
overestimate dietary iron contributions rather than potentially falsely attribute the
fluctuations of hemoglobin, transferrin, and ferritin to supplement ingestion.
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CHAPTER 7

CONCLUSION AND RECOMMENDATIONS
Pregnancy, birth, and the postpartum period present considerable physiological
challenges to women. Iron deficiency is often a byproduct of the demands associated with
human reproduction. Iron deficiency can be particularly problematic for women with
high IBIs, those who do not exclusively breastfeed, are obese, or are low income
individuals (Allen, 2000; Bodnar, Siega-Riz, Miller, Cogswell, & McDonald, 2002). Iron
deficiency can also negatively affect the children of iron deficient mothers (Rasmussen,
2001; Lewis et al., 2002; Golub, Hogrefe, Germann, Capitanio, & Lozoff, 2006; Colomer,
1990). Currently, many maternal placentophagy advocates claim that encapsulated
placenta is an excellent source of iron for postpartum mothers (Selander et al., 2013). To
date, however, there have been no rigorous scientific studies that have investigated this
claim.
The results of this study help fill major gaps of knowledge in the practice of human
maternal placentophagy. The current study suggests that encapsulated placenta
supplementation neither significantly improves, nor impairs postpartum maternal iron
status for women consuming at least adequate amounts of dietary iron. It is possible that
participants’ placenta was not necessarily a superior source of iron than a beef or soy-free
vegetarian placebo supplement of the same daily intake. This may mean that, among
women with adequate dietary iron intake, the bioavailability of iron present in the
placebo supplement is roughly equal to the bioavailability of iron in the placenta
supplement.
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OTC oral iron supplements are commonly used by women around the world, and are
of particular importance for pregnant and postpartum women experiencing iron
deficiency and IDA. One of the original goals of this study was to examine how placenta
supplements compared to standard oral iron supplements in order to deduce whether
placenta supplements are a viable option for the restoration of women’s iron status
postpartum, as this alternative form of iron supplementation may appeal to many mothers
looking for a more “natural” way to manage postpartum iron deficiency. While the small
size of the OTC iron supplement group served only as case studies for comparison to the
study’s Placenta and Placebo groups, it appears that, among women with adequate dietary
iron intake, encapsulated placenta supplements offer neither a superior, nor inferior,
source of oral iron supplementation. Unfortunately, the question of whether placenta
supplements are superior, equal, or inferior to standard iron supplements for women with
postpartum iron deficiency or IDA was beyond the scope of this study.
Future research might include focusing upon clinically diagnosed iron deficient and
IDA participants. Such studies would allow researchers to examine how well
encapsulated placenta supplements compare to traditional iron supplements among
women whose iron status is the most severely compromised. In addition to such clinical
studies, the research of placentophagy would benefit from the ethnographic study of
women engaging in placentophagy as well as placentophagy advocates. Such
ethnographies could examine topics such as women’s motivations for engaging in
placentophagy, and maternal health decision-making.
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Background Information Questionnaire
An Investigation of the Effects of Human Maternal Placentophagy in Postpartum
Maternal Health and Recovery
University of Nevada, Las Vegas

Please answer the following questions as accurately as possible
Age: _____

Height: _____ ft ______ in

Weight: _____ lbs

With which ethnicity do you most closely identify?
__ American Indian/Alaska Native

__ Caucasian

__ Middle Eastern

__ Asian

__ Hispanic/Latina

__ Other ___________

__ African American

__ Hawaiian/Pacific Islander

What is the highest level of education you have completed?
__ Grammar School

__ Bachelor’s degree

__ Doctoral degree

__ High School or equivalent

__ Master’s degree

__ Professional degree (MD, JD, etc.)

__ Some college

__ Vocational/technical school

Which of the following income groups includes your total annual family income:
__ Under $10,000

__ $30,001—$40,000

__ $60,001—$70,000

__ $10,000—$20,000

__ $40,001—$50,000

__ $70,001—$80,000

__ $20,001—$30,000

__ $50,001—$60,000

__ Over $80,000

Please indicate your marital status:
__ Single, never married

__ Married or domestic partnership

__ Separated

__ In a committed relationship, not cohabiting

__ Divorced

__ Widowed

Total number of people in the household: _____
Zip Code: _______________
Do you currently consume alcoholic beverages?
If yes, how often (circle one)?
!
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Yes
frequently

No
occasionally

rarely

Do you currently smoke cigarettes?

Yes

No

In the 3 months before your most recent pregnancy, did you take a multivitamin
containing folic acid or a folic acid supplement?
Never

Rarely

Occasionally

Is this your first pregnancy?

Almost every day

Yes

Daily

No

If this is not your first pregnancy, how many times have you given live birth? ___
Please list the dates that you have given live birth:
MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

MM / DD / YYYY .

Did you have complications with any of your pregnancies?

Yes

No

If yes, please explain briefly:
________________________________________________________________________
________________________________________________________________________
Have you ever ingested placenta, in any form, after any of your pregnancies? Yes

No

If yes, after which pregnancy did you ingest placenta? ______________________
Did you experience any effects that you attributed to placentophagy? Yes

No

Please describe: ____________________________________________________
__________________________________________________________________
Have you been diagnosed with, or do you suspect you may have an iron-related disorders
(e.g., hemochromatosis, iron deficiency, iron deficiency anemia)?

Yes

If yes, was this condition diagnosed by a medical practitioner? Yes

No
No

If yes, please describe: _______________________________________________
__________________________________________________________________
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Do you have any chronic health conditions?

Yes

No

If yes, please describe them here: ______________________________________
__________________________________________________________________
__________________________________________________________________
Have you received a blood transfusion within the past year?

Yes

If yes, when did you receive the most recent transfusion?

No

MM / YY .

Are you currently consuming a special diet (e.g., vegan, vegetarian, etc.)? Yes

No

If yes, please explain: ________________________________________________
__________________________________________________________________
Did your diet changed after learning that you were pregnant?

Yes

No

If yes, please explain how?
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
How much has your diet changed since pre-pregnancy (circle one)?
drastically

moderately

Are you currently taking any medications?

minimally
Yes

none

No

If yes, please list the medication(s) you are taking: _________________________
__________________________________________________________________
__________________________________________________________________
Are you currently taking any nutritional supplements (including multivitamins): Yes No
If yes, please list them here, and indicate the brand and dose: ________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
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Please mark any of the following conditions that you have experienced, and indicate the
severity and whether the condition was diagnosed by a medical professional:
___
___

Depression
Antenatal (pregnancy)
depression

Mild

Moderate

Severe

___ Diagnosed

Mild

Moderate

Severe

___ Diagnosed

___

Postnatal depression

Mild

Moderate

Severe

___ Diagnosed

___

Maternity blues

Mild

Moderate

Severe

___ Diagnosed

Mild

Moderate

Severe

___ Diagnosed

___

Premenstrual dysphoric
disorder (PMDD)

___

Anxiety

Mild

Moderate

Severe

___ Diagnosed

___

Bipolar disorder

Mild

Moderate

Severe

___ Diagnosed

___

Schizophrenia

Mild

Moderate

Severe

___ Diagnosed

___

Anemia

Mild

Moderate

Severe

___ Diagnosed

___

Insomnia/sleep disorder

Mild

Moderate

Severe

___ Diagnosed

___

Thyroid disorder

Mild

Moderate

Severe

___ Diagnosed

___

Endocrine disorder

Mild

Moderate

Severe

___ Diagnosed

Mild

Moderate

Severe

___ Diagnosed

___

Reproductive disorder (e.g.,
PCOS, endometriosis)

Do you have an allergy or sensitivity to Ferrous sulfate (iron)?
What is the starting date of your last menstrual period?
What is your projected due date?

Yes

No

MM / DD / YY

MM / DD / YY

Where do you plan to give birth?
__ In a hospital with a physician

__ At home

__ In a hospital with a midwife

__ At a birthing center

__ Other Please describe: _________________________________________
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Biomedical IRB – Full Board Review
Approval Notice
NOTICE TO ALL RESEARCHERS:
Please be aware that a protocol violation (e.g., failure to submit a modification for any
change) of an IRB approved protocol may result in mandatory remedial education,
additional audits, re-consenting subjects, researcher probation, suspension of any
research protocol at issue, suspension of additional existing research protocols,
invalidation of all research conducted under the research protocol at issue, and further
appropriate consequences as determined by the IRB and the Institutional Officer.
DATE:

July 23, 2013

TO:

Dr. Daniel Benyshek, Anthropology

FROM:

Office of Research Integrity - Human Subjects

RE:

Notification of IRB Action
Protocol Title: An Investigation of the Effects of Human Maternal
Placentophagy on Postpartum Health and Recovery
Protocol #: 1305-4465M
Expiration Date: July 22, 2014
________________________________________________________________________
This memorandum is notification that the project referenced above has been reviewed
and approved by the UNLV Biomedical Institutional Review Board (IRB) as indicated in
Federal regulatory statutes 45 CFR 46 and UNLV Human Research Policies and
Procedures.
The protocol is approved for a period of one year and expires July 22, 2014. If the abovereferenced project has not been completed by this date you must request renewal by
submitting a Continuing Review Request form 60 days before the expiration date.
PLEASE NOTE:
Upon approval, the research team is responsible for conducting the research as stated in
the protocol most recently reviewed and approved by the IRB, which shall include using
the most recently submitted Informed Consent/Assent forms and recruitment materials.
The official versions of these forms are indicated by footer which contains approval and
expiration dates.
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Should there be any change to the protocol, it will be necessary to submit a Modification
Form through ORI - Human Subjects. No changes may be made to the existing protocol
until modifications have been approved by the IRB. Modified versions of protocol
materials must be used upon review and approval. Unanticipated problems, deviations to
protocols, and adverse events must be reported to the ORI – HS within 10 days of
occurrence.
If you have questions or require any assistance, please contact the Office of Research
Integrity - Human Subjects at IRB@unlv.edu or call 895-2794.
Office of Research Integrity - Human Subjects
4505 Maryland Parkway • Box 451047 • Las Vegas, Nevada 89154-1047
(702) 895-2794 • FAX: (702) 895-0805
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Biomedical IRB – Expedited Review
Continuing Review Approved
NOTICE TO ALL RESEARCHERS:
Please be aware that a protocol violation (e.g., failure to submit a modification for any
change) of an IRB approved protocol may result in mandatory remedial education,
additional audits, re-consenting subjects, researcher probation suspension of any
research protocol at issue, suspension of additional existing research protocols,
invalidation of all research conducted under the research protocol at issue, and further
appropriate consequences as determined by the IRB and the Institutional Officer.
DATE:
TO:
FROM:
RE:

June 19, 2014
Dr. Daniel Benyshek, Anthropology
Office of Research Integrity – Human Subjects
Notification of IRB Action
Protocol Title: An Investigation of the Effects of Human Maternal
Placentophagy on Postpartum Health and Recovery
Protocol #: 1305-4465M
Expiration Date: June 18, 2015
________________________________________________________________________
Continuing review of the protocol named above has been reviewed and approved.
This IRB action will reset your expiration date for this protocol. The protocol is approved
for a period of one year from the date of IRB approval. The new expiration date for this
protocol is June 18, 2015. If the above-referenced project has not been completed by this
date you must request renewal by submitting a Continuing Review Request form 30 days
before the expiration date.
PLEASE NOTE:
Upon approval, the research team is responsible for conducting the research as stated in
the protocol most recently reviewed and approved by the IRB, which shall include using
the most recently submitted Informed Consent/Assent forms and recruitment materials.
The official versions of these forms are indicated by footer which contains current
approval and expiration dates.
Should there be any change to the protocol, it will be necessary to submit a Modification
Form through ORI - Human Subjects. No changes may be made to the existing protocol
until modifications have been approved by the IRB. Modified versions of protocol
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materials must be used upon review and approval. Unanticipated problems, deviations to
protocols, and adverse events must be reported to the ORI – HS within 10 days of
occurrence.
If you have questions or require any assistance, please contact the Office of Research
Integrity - Human Subjects at IRB@unlv.edu or call 895-2794.
Office of Research Integrity - Human Subjects
4505 Maryland Parkway • Box 451047 • Las Vegas, Nevada 89154-1047
(702) 895-2794 • FAX: (702) 895-0805
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